Main Cox regression analyses on mortality for class III idiopathic PAH patients treated with bosentan or epoprostenol
Bosentan(n) | Epoprostenol(n) | No of events | Hazard ratio | 95% CL | p value | |
---|---|---|---|---|---|---|
CL, confidence limits; mPAP, mean pulmonary artery pressure; mRAP, mean right atrial pressure. | ||||||
*In the entire database, patients started bosentan on or after September 1999 and epoprostenol on or after January 1995. For the same time period all patients started treatment on or after September 1999, and for different time periods patients started bosentan on or after September 1999 and started epoprostenol between January 1995 and September 1999. | ||||||
†Using the parameters age, sex, and baseline cardiac index, mPAP, mRAP, pulmonary vascular resistance, and WHO functional class. | ||||||
‡Using the stepwise model parameters given in the footnote above + walk test. | ||||||
§Parameters of cardiac index, mPAP, and mRAP suggested by the literature.11 | ||||||
Entire database* | ||||||
No adjustment | 139 | 346 | 85 | 1.9 | 1.1, 3.5 | 0.025 |
Model adjusted for haemodynamics§ | 136 | 314 | 76 | 2.2 | 1.2, 4.0 | 0.014 |
Stepwise model† | ||||||
mPAP | 136 | 314 | 76 | 2.3 | 1.3, 4.2 | 0.006 |
Stepwise model‡ | ||||||
mPAP, walk test | 136 | 169 | 46 | 2.7 | 1.4, 5.4 | 0.005 |
Patients treated during same time period* | ||||||
No adjustment | 139 | 81 | 26 | 2.5 | 1.1, 5.6 | 0.022 |
Model adjusted for haemodynamics§ | 136 | 78 | 25 | 2.3 | 0.9, 5.6 | 0.073 |
Stepwise model† | ||||||
None | 136 | 78 | 25 | 2.4 | 1.1, 5.4 | 0.033 |
Stepwise model‡ | ||||||
Walk test | 136 | 29 | 18 | 2.1 | 0.7, 6.6 | 0.206 |
Patients treated during different time periods* | ||||||
No adjustment | 139 | 217 | 67 | 1.9 | 1.0, 3.5 | 0.035 |
Model adjusted for haemodynamics§ | 136 | 196 | 60 | 2.2 | 1.2, 4.3 | 0.016 |
Stepwise model† | ||||||
mPAP, mRAP | 136 | 196 | 60 | 2.3 | 1.2, 4.3 | 0.012 |
Stepwise model‡ | ||||||
mPAP, mRAP | 136 | 117 | 39 | 2.7 | 1.3, 5.7 | 0.007 |